KING OF PRUSSIA, Pa.
,
Jan. 5
/PRNewswire/ — Prism Pharmaceuticals
announced today that the U.S. Food & Drug Administration (FDA) has approved
the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a
novel, patent-protected, cosolvent free formulation of the antiarrhythmic
agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone(R)
Intravenous. NEXTERONE is indicated for the treatment and prophylaxis Read the rest of this entry »
February 17, 2009 11:00 AM ET
Keith A. Katkin – President and Chief Executive Officer
Christine G. Ocampo – Vice President, Finance
Randall E. Kaye, M.D. – Senior Vice President Clinical Research and Medical Affairs, Chief Medical Officer
Ronald L. Chez – Chicago Investor
Good morning. My name is Joshua and I will be your conference operator today. At this time, I would like to welcome everyone to the AVANIR Pharmaceuticals Fiscal 2009 First Read the rest of this entry »
Prism intends to submit a supplemental new drug application (NDA) for the premixed configurations which will form the focus of the commercial launch of Nexterone as a complete product line.
Prism is currently implementing a full scale manufacturing development program with the medication delivery business of Baxter Healthcare, a developer of premix technologies.
The FDA approval of Nexterone triggers a second $10 million milestone payment from Read the rest of this entry »
LONDON (MarketWatch) — Denmark’s H. Lundbeck said that it will buy Ovation Pharmaceuticals Inc. for up to $900 million. Lundbeck will make an upfront payment of $600 million upon closing. Additional payments of up to $300 million within one year of closing are contingent upon the achievement of certain product regulatory milestones relating to FDA approval of Ovation’s Sabril treatment for adults with refractory complex partial seizures and children Read the rest of this entry »
It’s not quite Pfizer buying Wyeth, but two more drugmakers announced another deal Monday designed to bolster an aging pipeline.
Danish drug maker Lundbeck has agreed to acquire Ovation Pharmaceuticals Inc. for up to $900 million. The deal,
, is expected to close in March 2009.
Lundbeck, based in Copenhagen, is preparing for the 2012 patent expiration of depression treatment Lexapro/Cipralex, which made up nearly two-thirds of Lundbecks Read the rest of this entry »
The global outlook series on Pharmaceuticals provides a collection of
statistical anecdotes, market briefs, and concise summaries of research
findings. The report provides a bird’s eye view of the pharmaceutical
industry, and highlights global trends impacting the marketplace, such
as, patent expiry of blockbuster global drugs, rising demand for old age
related medications and cardiovascular drugs, and the rise Read the rest of this entry »
Government medical advisers recommended a ban on Darvon, a prescription drug that has been used to treat pain for more than 50 years but has been linked to addiction. An advisory panel to the
voted 14 to 12 to recommend its withdrawal. The F.D.A. is not required to follow such recommendations, but often does.
Darvon, approved in 1957 and now mainly marketed as Darvocet, is one of the 25 most commonly prescribed medications.
had petitioned Read the rest of this entry »
OSI Pharmaceuticals is committed to “shaping medicine and changing
lives” by discovering, developing and commercializing high-quality and
novel pharmaceutical products designed to extend life and/or improve the
quality of life for patients with cancer and diabetes/obesity. The
Company’s oncology programs are focused on developing molecular targeted
therapies designed to change the paradigm of cancer care. OSI’s Read the rest of this entry »
Each Thursday at 8:30 a.m. EST, the government tells us about how many people went through one of the most unpleasant experiences
of their lives: filing for unemployment help for the first time. It’s essentially a survey, since state unemployment is managed
by your state, not the federal government.
The report runs like clockwork, but it¿s notoriously inaccurate. For one
thing, the number often has wide Read the rest of this entry »
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as “will”, “would”,
“should”, “expects”, “anticipates”, “intends”, “plans”, “believes”,
“may”, “estimates”, “predicts”, “projects”, or similar expressions
intended to identify forward-looking statements. Such statements, Read the rest of this entry »